Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.51 |
| ▸ | TACR1 | P25103 | 3/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
| ▸ | MMP3 | P08254 | 1/20 | 0.33 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.33 |
| ▸ | MC4R | P32245 | 1/20 | 0.33 |
| ▸ | MC5R | P33032 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.33 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2295821 | 1.00 | PARP1 (0.51) | PARP1TACR1CYP2D6SLC6A2SLC6A4 | |
| SCHEMBL873440 | 1.00 | PARP1 (0.51) | PARP1TACR1CYP2D6SLC6A2SLC6A4 | |
| SCHEMBL23569456 | 0.89 | PARP1 (0.49) | PARP1MC4RMC5RNR1H2NR1H3 | |
| SCHEMBL21273838 | 0.88 | PARP1 (0.50) | PARP1MC4RMC5RNR1H2NR1H3 | |
| SCHEMBL27786601 | 0.87 | PARP1 (0.47) | PARP1MC4RMC5RNR1H2NR1H3 | |
| SCHEMBL24543368 | 0.86 | PARP1 (0.53) | PARP1NR1H2NR1H3 | |
| SCHEMBL30803666 | 0.86 | PARP1 (0.53) | PARP1NR1H2NR1H3 | |
| SCHEMBL1990452 | 0.84 | PARP1 (0.54) | PARP1KMT2ANR1H2 | |
| SCHEMBL1990451 | 0.84 | PARP1 (0.54) | PARP1KMT2ANR1H2 | |
| SCHEMBL336577 | 0.84 | PARP1 (0.54) | PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3727380-B1 | PURINE INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | MERCK SHARP & DOHME LLC (US) | 2025-09-24 | — | — | EP | disclosed |
| US-20240124443-A1 | PLASMIN INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | SCINNOHUB PHARMACEUTICAL CO., LTD (CN) | 2024-04-18 | — | — | US | disclosed |
| EP-4289850-A1 | PLASMIN INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | Scinnohub Pharmaceutical Co., Ltd (CN) | 2023-12-13 | — | — | EP | disclosed |
| US-11814367-B2 | Inhibitors of glycogen synthase 1 (GYS1) and methods of use thereof | MAZE THERAPEUTICS, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| CN-116848122-A | Plasmin inhibitor, preparation method and application thereof | 赛诺哈勃药业（成都）有限公司 | 2023-10-03 | — | — | CN | disclosed |
| WO-2022166845-A1 | PLASMIN INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | 赛诺哈勃药业（成都）有限公司 | 2022-08-11 | — | — | WO | disclosed |
| US-11230547-B2 | Purine inhibitors of human phosphatidylinositol 3-kinase delta | MERCK SHARP & DOHME CORP. (US) | 2022-01-25 | — | — | US | disclosed |
| US-20200392144-A1 | PURINE INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | MERCK SHARP & DOHME CORP. (US) | 2020-12-17 | — | — | US | disclosed |
| US-9624200-B2 | Therapeutic piperazines | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2017-04-18 | — | — | US | disclosed |
| EP-1989188-B1 | THERAPEUTIC PIPERAZINES AS PDE4 INHIBITORS | DART NEUROSCIENCE CAYMAN LTD (KY) | 2015-07-22 | — | — | EP | disclosed |
| EP-1871765-A2 | 3-(INDAZOL-5-YL)-(1,2,4)TRIAZINE DERIVATIVES AND RELATED COMPOUNDS AS PROTEIN KINASE INHIBITORS FOR THE TREATMENT OF CANCER | SCHERING CORPORATION (US) | 2008-01-02 | — | — | EP | disclosed |
| WO-2007100852-A1 | THERAPEUTIC PIPERAZINES AS PDE4 INHIBITORS | HELICON THERAPEUTICS, INC. (US) | 2007-09-07 | — | — | WO | disclosed |
| EP-1829877-A1 | BICYCLIC PYRROLE DERIVATIVES | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2007-09-05 | — | — | EP | disclosed |
| US-20070203124-A1 | Therapeutic Piperazines | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2007-08-30 | — | — | US | disclosed |
| US-20070082908-A1 | Bicycle pyrazole derivative | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-04-12 | — | — | US | disclosed |
| EP-1701944-A2 | 2-(AMINO-SUBSTITUTED)-4-ARYL PYRAMIDINES AND RELATED COMPOUNDS USEFUL FOR TREATING INFLAMMATORY DISEASES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2006-09-20 | — | — | EP | disclosed |
| WO-2006081230-A2 | 3-(INDAZOL-5-YL)-(1,2, 4) TRIAZINE DERIVATIVES AND RELATED COMPOUNDS AS PROTEIN KINASE INHIBITORS FOR THE TREATMENT OF CANCER | SCHERING CORPORATION (US) | 2006-08-03 | — | — | WO | disclosed |
| US-20060058308-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2006-03-16 | — | — | US | disclosed |
| US-20060040968-A1 | 2-(Amino-substituted)-4-aryl pyrimidines and related compounds useful for treating inflammatory diseases | MILLENNIUM PHARMACEUTICALS, INC. | 2006-02-23 | — | — | US | disclosed |
| WO-2005066139-A2 | 2-(AMINO-SUBSTITUTED)-4-ARYL PYRAMIDINES AND RELATED COMPOUNDS USEFUL FOR TREATING INFLAMMATORY DISEASES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200392144-A1 | PURINE INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | PIK3CD, PIK3CA, PI4KA | PARP1 480/4885TACR1 2329/4885CYP2D6 1857/4885 |
| US-20060058308-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV3, TRPV2 | PARP1 2400/4885TACR1 181/4885CYP2D6 1701/4885 |
| US-11814367-B2 | Inhibitors of glycogen synthase 1 (GYS1) and methods of use thereof | GYS2, GYS1, PYGL | PARP1 2809/4885TACR1 4794/4885CYP2D6 1746/4885 |
| US-20070203124-A1 | Therapeutic Piperazines | PDE4A, PDE4B, PDE12 | PARP1 1492/4885TACR1 485/4885CYP2D6 1881/4885 |
| US-20060040968-A1 | 2-(Amino-substituted)-4-aryl pyrimidines and related compounds useful for treating inflammatory diseases | PRKCZ, PRKCQ, PRKCE | PARP1 1880/4885TACR1 4188/4885CYP2D6 2087/4885 |
| US-20240124443-A1 | PLASMIN INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | F2, PLG, PLAT | PARP1 453/4885TACR1 632/4885CYP2D6 982/4885 |
| US-20070082908-A1 | Bicycle pyrazole derivative | DPP4, DPP7, DPP3 | PARP1 1602/4885TACR1 1488/4885CYP2D6 43/4885 |
| US-11230547-B2 | Purine inhibitors of human phosphatidylinositol 3-kinase delta | PIK3CD, PIK3CA, PI4KA | PARP1 480/4885TACR1 2329/4885CYP2D6 1857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.